Remus Pharmaceuticals Ltd
Incorporated in 2015, Remus Pharmaceuticals Limited is engaged in the marketing and distributing of finished formulations of pharmaceutical drugs.[1]
- Market Cap ₹ 1,171 Cr.
- Current Price ₹ 7,948
- High / Low ₹ 8,747 / 1,711
- Stock P/E 69.6
- Book Value ₹ 557
- Dividend Yield 0.08 %
- ROCE 84.3 %
- ROE 87.9 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 78.0%
- Debtor days have improved from 36.8 to 27.9 days.
- Promoter holding has increased by 0.99% over last quarter.
Cons
- Stock is trading at 14.3 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
12 | 18 | 25 | 45 | 64 | |
12 | 18 | 21 | 34 | 43 | |
Operating Profit | 0 | 1 | 4 | 11 | 20 |
OPM % | 3% | 4% | 17% | 23% | 32% |
1 | 1 | 1 | 2 | 4 | |
Interest | 0 | 0 | 0 | 0 | 0 |
Depreciation | 0 | 0 | 0 | 0 | 1 |
Profit before tax | 1 | 1 | 5 | 11 | 23 |
Tax % | 27% | 25% | 26% | 26% | 25% |
1 | 1 | 3 | 8 | 17 | |
EPS in Rs | 810.00 | 1,060.00 | 34.30 | 78.34 | 114.19 |
Dividend Payout % | 0% | 0% | 0% | 3% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 51% |
TTM: | 41% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 158% |
TTM: | 98% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 78% |
Last Year: | 88% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Equity Capital | 0 | 0 | 1 | 1 | 1 |
Reserves | 2 | 3 | 6 | 18 | 81 |
0 | 0 | 0 | 8 | 1 | |
3 | 8 | 9 | 8 | 15 | |
Total Liabilities | 5 | 11 | 16 | 35 | 98 |
0 | 0 | 0 | 3 | 2 | |
CWIP | 0 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 3 | 21 | 43 |
5 | 11 | 12 | 11 | 53 | |
Total Assets | 5 | 11 | 16 | 35 | 98 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
1 | -0 | 5 | 5 | 2 | |
-1 | -0 | -5 | -15 | -21 | |
0 | -0 | -0 | 12 | 39 | |
Net Cash Flow | 1 | -0 | 0 | 2 | 21 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Debtor Days | 50 | 71 | 43 | 39 | |
Inventory Days | 23 | 36 | 47 | 5 | |
Days Payable | 68 | 164 | 139 | 60 | |
Cash Conversion Cycle | 5 | -56 | -48 | -16 | |
Working Capital Days | 22 | -18 | -38 | 8 | |
ROCE % | 46% | 92% | 69% |
Business Segments
A) APIs (84.5% of FY22 revenue)[1] Co has 54 products in this segment
B) Finished Pharmaceutical Formulations(15.5% of FY22 revenue)[1]